While Cementing Partnership With U.S. Biotech Firm, Cash-rich Simcere Launches Twin Acquisitions Targeting Biosimilar, Vaccine Outfits In China

BEIJING - Fresh after cementing a new partnership with a San Francisco-based biologics firm, Simcere Pharmaceutical Group has launched twin acquisitions aimed at simultaneously expanding into the biosimilar and vaccine sectors, according to Simcere's leadership